Search results for: 'Biological antibody reagents US'
- Related search terms
- antibody market
- antibody market
- antibody drug conjugates contract development and manufacturing organization
- antibody drug conjugates contract development and manufacturing organization 2025
- antibody drug conjugate contract development and manufacturing organization
-
19 Aug 2022  |  North America  |  Market Research
Global Antibody Therapeutics Growth Opportunities
The Evolution of Next-generation Immuno-oncology Therapies for Multiple Tumor Antigens is Poised to Drive Market Growth
Market growth is likely to be fueled by the growing utilization of cost-effective and efficient continuous manufacturing processes and single-use bioreactors for production, which will also reduce the time between development and commercialization. Favorable regulatory reforms in emerging Asian countries are encouraging the manufacture and introduc...
$2,450.00 -
25 Jun 2024  |  Global  |  Market Research
Growth Opportunities in Biologics Contract Development and Manufacturing Organizations, 2024 2029
Risk-sharing Business Models for Next-generation Biologics Will Drive Bio-CDMO Growth and Spur Future Potential
By 2023, biologics constituted 44% of the therapeutic pipeline, with antibodies and recombinant proteins as leading categories. Nevertheless, advancements in these fields decelerated, with most of the expansion happening in heterologous cell treatments, synthetic nucleic acids, and viruses. The global biologics pipeline will shift toward more compl...
$4,950.00 -
10 May 2023  |  Global  |  Market Research
Growth Opportunities in the Biologics Contract Development and Manufacturing Organization Sector
Value Chain Expansion to Support Next generation Biologics Drives Future Growth Potential
This research service provides an overview of the global biologics contract development and manufacturing organization (bio-CDMO) market and a 6-year market revenue forecast (2023 to 2028). The geographic scope covers three key regions, namely North America (NA); Europe; and Asia-Pacific (APAC). The report offers a detailed segment analysis of...
$4,950.00 -
21 Dec 2022  |  Global  |  Technology Research
Antibody-drug Conjugates: Technology Growth Opportunities
Disruptive Technologies and a Conducive Funding Environment are Fostering Growth
Antibody-drug conjugates (ADCs) are therapies that target cancer cells with antigen-specific antibodies and highly toxic payloads. ADCs are currently generating interest among drug developers, contract manufacturing companies, regulatory agencies, and other stakeholders. The rise in the number of drug approvals has also sparked interest in further ...
$4,950.00 -
25 Jul 2024  |  Global  |  Technology Research
Engineered Antibody Therapeutics for Cancer
Technology advances and increasing interest from Tier I pharmaceuticals are driving the growth of engineered antibodies
This study analyzes the emergence of engineered antibody therapeutics for cancer, examining the factors driving their adoption. The limitations of monoclonal antibodies have led to an increasing demand for novel formats. Companies are developing multispecific antibodies, such as bispecifics and trispecifics, and antibody fragments, such as Fab and ...
$4,950.00 -
24 Jul 2020  |  North America  |  Market Research
Curative Oncology and Rare Disease Therapies Transforming the Global Biologics Market, 2020–2024
Strategic Collaborations with Specialty Bio-CDMOs will Continue to Drive Growth Opportunities in Antibody-drug Conjugates and Gene Therapies
With this research service, Frost & Sullivans Transformational Health team provides critical insights into the global biologics industry highlighting the growth opportunities, market revenue segmentation, and technology trends influencing its growth. The global biologics market covered in this study includes 4 major segments – antibody therapies, r...
$4,950.00 -
29 Sep 2015  |  Global  |  Technology Research
Advances in monoclonal antibody therapeutics
Monoclonal antibody therapeutics are being used for treatment of a wide array of diseases, specially in therapeutic areas such as oncology, immunology (including autoimmune and inflammatory diseases, as well as, transplant rejection) and neuroscience. The development of these new molecular agents, successfully directed to specific cellular targets,...
$4,950.00 -
09 Nov 2022  |  Global  |  Technology Research
Emerging Therapeutics for Rare Neuromuscular Diseases: Pipeline Analysis
Strategic partnering and new product development will enable better biologics for personalized and targeted treatment
Muscle weakness, cramps, and impaired musculoskeletal functions that occur due to rare defects in nerve and muscle cells characterize neuromuscular disorders (NMDs). The disorders are largely classified as motor neuron diseases, hereditary ataxias, peripheral nerve disorders, neuromuscular junction transmission disorders, and myopathies. NMDs prese...
$4,950.00 -
05 Dec 2014  |  North America  |  Market Research
US Hemostasis Market
Increase in the Number of Patients within the Healthcare System Triggers Reagent Market Growth
The Affordable Care Act has created an upswing in the number of patients entering the US healthcare system, boosting the volume of routine and specialized testing performed in laboratories. This market insight analyzes the instrumentation and reagent segment activity within the US hemostasis market. Key trends and a comparative analysis between the...
$2,450.00 -
22 Sep 2022  |  North America  |  Market Research
AI Commercial Use Cases, Impact Analyses, and Growth Opportunities in Clinical Genomics
Integration of Clinical Genomics and AI will lead to definitive Transformational Growth in the Next Decade
Clinical genomics regained significance during the pandemic with the development of the mRNA COVID-19 vaccine, and several non-invasive at-home test kits; an unprecedented feat in recent times. Genomics will take center stage, as large genome sequencing and research will continuously create data for new therapeutics. Artificial Intelligence (AI) an...
$2,450.00